Frontiers | Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents
Upvotes: 1
Favorite this post:
Mark as read:
Your rating:
Add this post to a custom list 
StoryNote Upvotes: 1